Glioma Biopsy Based on Hybrid Dual Time-Point FET-PET/MRI—A Proof of Concept Study
Open Access
- 11 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
Abstract
Neuroimaging based on O-[2-(18F)fluoroethyl]-L-tyrosine (FET)-PET provides additional information on tumor grade and extent compared with MRI. Dynamic PET for biopsy target selection further improves results but is often clinically impractical. Static FET-PET performed at two time-points may be a good compromise, but data on this approach are limited. The aim of this study was to compare the histology of lesions obtained from two challenging glioma patients with targets selected based on hybrid dual time-point FET-PET/MRI. Five neuronavigated tumor biopsies were performed in two difficult cases of suspected glioma. Lesions with (T1-CE) and without contrast enhancement (T1 and T2-FLAIR) on MRI were selected. Dual time-point FET-PET imaging was performed 5–15 min (PET10) and 45–60 min (PET60) after radionuclide injection. The most informative FET-PET/MRI images were coregistered with MRI in time of biopsy planning. Five biopsy targets (three from high uptake and two from moderate uptake FET areas) thought to represent the most malignant sites and tumor extent were selected. Histopathological findings were compared with FET-PET and MRI images. Increased FET uptake in the area of non-CE locations on MRI correlated well with high-grade gliomas localized as far as 3 cm from T1-CE foci. Selecting a target in the motor cortex based on FET kinetics defined by dual time-point PET resulted in a grade IV diagnosis after previous negative biopsies based on MRI. An additional grade III diagnosis was obtained from an area of glioma infiltration with moderate FET uptake (between 1 and 1.25 SUV). These findings seem to show that dual time-point FET-PET-based biopsies can provide additional and clinically useful information for glioma diagnosis. Selection of targets based on dual time-point images may be useful for determining the most malignant tumor areas and may therefore be useful for resection and radiotherapy planning.This publication has 29 references indexed in Scilit:
- Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapyRadiotherapy and Oncology, 2013
- Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of GliomaJournal of Nuclear Medicine, 2012
- MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?European Journal of Nuclear Medicine and Molecular Imaging, 2012
- Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and MetaanalysisJournal of Nuclear Medicine, 2012
- Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomasNeuro-Oncology, 2011
- Biopsy Targeting GliomasInvestigative Radiology, 2010
- FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour gradingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Multiplex Ligation-Dependent Probe Amplification: A Diagnostic Tool for Simultaneous Identification of Different Genetic Markers in Glial TumorsThe Journal of Molecular Diagnostics, 2006
- O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomasBrain, 2005
- Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003